Skip to main content

01.12.2015 | Case report | Ausgabe 1/2015 Open Access

BMC Musculoskeletal Disorders 1/2015

Systemic autoimmune disease in asbestosis rapidly responding to anti-interleukin-1beta antibody canakinumab: a case report

BMC Musculoskeletal Disorders > Ausgabe 1/2015
Laura Niccoli, Emanuele Cassarà, Olga Kaloudi, Carlotta Nannini, Micaela Romagnoli, Fabrizio Cantini
Wichtige Hinweise

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

LN, OK, and MR included in the text the clinical data and gave the final approval of the manuscript version. FC participated to the treatment decision and gave his approval of the final manuscript version after revising it critically. EC and CN wrote the manuscript draft and gave their final approval to the modified text. All authors read and approved the final manuscript.



Asbestosis is characterized by lung and pleural fibrosis and by immune system dysregulation, with autoantibody production and systemic immune-mediated disease. No specific therapies are available for asbestosis. Recently, the pivotal pathogenic role exerted by interleukin-1beta has been recently reported.

Case presentation

We treated with anti-interleukin 1 beta targeted antibody canakinumab a 67 year old man with asbestosis and long lasting systemic autoimmune features. A dramatic improvement in clinical manifestations was observed at 1 week after the first injection, with complete clinical remission at 4 months.


This case suggests new perspectives for the treatment of asbestosis and its systemic features.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2015

BMC Musculoskeletal Disorders 1/2015 Zur Ausgabe

Neu im Fachgebiet Orthopädie und Unfallchirurgie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Orthopädie und Unfallchirurgie und bleiben Sie gut informiert – ganz bequem per eMail.